Literature DB >> 1639632

HLA-DR expression in human fetal thymocytes.

S H Park1, Y M Bae, T J Kim, I S Ha, S Kim, J G Chi, S K Lee.   

Abstract

We analyzed the expression of MHC class I (W6/32) and class II (HLA-DR) antigens on human fetal and postnatal thymocytes by fluorescence-activated cell sorting. Less than 5% of prenatal thymocytes expressed HLA-DR before week 12 of gestation. However, the number of HLA-DR-positive cells significantly increased during the late second and third trimester of gestation, when greater than 50% of prenatal thymocytes expressed HLA-DR. Such high-level expressions of HLA-DR in fetal thymocytes were also demonstrated by Northern-blot analysis and immunohistochemistry. After birth, the percentage of HLA-DR-positive cells in thymocytes decreased gradually. A high-level expression of class I antigen was also observed in thymocytes from the early stages of gestation, but, in contrast to MHC class II, a majority of postnatal thymocytes maintained high levels of class I antigen after birth.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1639632     DOI: 10.1016/0198-8859(92)90338-n

Source DB:  PubMed          Journal:  Hum Immunol        ISSN: 0198-8859            Impact factor:   2.850


  16 in total

Review 1.  Alternative memory in the CD8 T cell lineage.

Authors:  You Jeong Lee; Stephen C Jameson; Kristin A Hogquist
Journal:  Trends Immunol       Date:  2011-02-01       Impact factor: 16.687

2.  Thymic low affinity/avidity interaction selects natural Th1 cells.

Authors:  Byung Hyun Kang; Hyo Jin Park; Hye In Yum; Seung Pyo Park; Jin Kyun Park; Eun Ha Kang; Jae-Il Lee; Eun Bong Lee; Chung-Gyu Park; Kyeong Cheon Jung; Seong Hoe Park
Journal:  J Immunol       Date:  2015-05-13       Impact factor: 5.422

3.  Multipotent RAG1+ progenitors emerge directly from haemogenic endothelium in human pluripotent stem cell-derived haematopoietic organoids.

Authors:  Andrew G Elefanty; Edouard G Stanley; Ali Motazedian; Freya F Bruveris; Santhosh V Kumar; Jacqueline V Schiesser; Tyrone Chen; Elizabeth S Ng; Ann P Chidgey; Christine A Wells
Journal:  Nat Cell Biol       Date:  2020-01-06       Impact factor: 28.824

4.  Stable interactions and sustained TCR signaling characterize thymocyte-thymocyte interactions that support negative selection.

Authors:  Heather J Melichar; Jenny O Ross; Kayleigh T Taylor; Ellen A Robey
Journal:  J Immunol       Date:  2014-12-17       Impact factor: 5.422

5.  The SLAM-associated protein signaling pathway is required for development of CD4+ T cells selected by homotypic thymocyte interaction.

Authors:  Wei Li; M Hanief Sofi; Svend Rietdijk; Ninghai Wang; Cox Terhorst; Cheong-Hee Chang
Journal:  Immunity       Date:  2007-11       Impact factor: 31.745

Review 6.  MHC class II antigen presentation and immunological abnormalities due to deficiency of MHC class II and its associated genes.

Authors:  Xinjian Chen; Peter E Jensen
Journal:  Exp Mol Pathol       Date:  2008-04-13       Impact factor: 3.362

Review 7.  Human intrathymic development: a selective approach.

Authors:  J Plum; M De Smedt; G Leclercq; T Taghon; T Kerre; B Vandekerckhove
Journal:  Semin Immunopathol       Date:  2008-10-17       Impact factor: 9.623

8.  Innate-like CD4 T cells selected by thymocytes suppress adaptive immune responses against bacterial infections.

Authors:  Yu Qiao; Brian M Gray; Mohammed H Sofi; Laura D Bauler; Kathryn A Eaton; Mary X D O'Riordan; Cheong-Hee Chang
Journal:  Open J Immunol       Date:  2011-12-30

9.  CD4(+) T cells from MHC II-dependent thymocyte-thymocyte interaction provide efficient help for B cells.

Authors:  Eun Ji Kim; Bomi Choi; Hana Moon; You Jeong Lee; Yoon Kyeong Jeon; Seong Hoe Park; Tae Jin Kim; Kyeong Cheon Jung
Journal:  Immunol Cell Biol       Date:  2011-03-01       Impact factor: 5.126

10.  Generation of PLZF+ CD4+ T cells via MHC class II-dependent thymocyte-thymocyte interaction is a physiological process in humans.

Authors:  You Jeong Lee; Yoon Kyung Jeon; Byung Hyun Kang; Doo Hyun Chung; Chung-Gyu Park; Hee Young Shin; Kyeong Cheon Jung; Seong Hoe Park
Journal:  J Exp Med       Date:  2009-12-28       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.